Association of Apolipoprotein Cs with New-onset Type 2 Diabetes Mellitus: Findings from the Chinese Multi-provincial Cohort Study

Overview

Journal BMJ Open

Specialty General Medicine

Date 2021 Nov 17

PMID 34785554

Citations 1

Authors

Jiangtao Li

Dong Zhao

Jing Liu

Miao Wang

Jiayi Sun

Jun Liu

Yan Li

Qiuju Deng

Yue Qi

Affiliations

Soon will be listed here.

Abstract

Objectives: Apolipoprotein Cs (apoCs), especially apoC-II and apoC-III, as the components of triglyceride-rich lipoproteins, play a key role in the pathophysiology of diabetes. However, prospective studies examining direct associations between apoCs and diabetes are not reproducible. The aim of this study was to evaluate the impact of apoCs on the risk of developing diabetes in a middle-aged population, and to explore possible mediators responsible for the relationship between apoCs and diabetes.

Design: Prospective cohort study.

Setting: Community-based study carried out in Beijing.

Methods: ApoCs were measured in 1085 participants aged 45-74 years and free of type 2 diabetes mellitus (T2DM) at baseline from the Chinese Multi-Provincial Cohort Study-Beijing Project. Multivariate logistic regression was performed to examine the association of apoCs with a 5-year risk of new-onset T2DM. The impacts of triglycerides, insulin and high-sensitivity C reactive protein (hs-CRP) on the association between apoC-III and the risk of T2DM were explored by a mediation test.

Results: During the 5 years of follow-up, 97 (8.9%) participants developed T2DM. ApoC-III was significantly associated with the risk of developing T2DM after multivariable adjustment (OR=1.40; 95% CI 1.07 to 1.82). This association was mainly mediated by triglyceride levels with a significant indirect effect (OR 1.61; 95% CI 1.19 to 2.18), followed by hs-CRP and insulin.

Conclusions: Our findings demonstrated that higher serum apoC-III was independently associated with increased 5-year risk of new-onset T2DM in the Chinese population, and triglyceride plays a crucial role in mediating this relationship. More attention should be paid to preventive strategies of T2DM targeting apoC-III.

Citing Articles

Relationship Between Resting Heart Rate and Microalbuminuria in Adults With Hypertension: National Health and Nutrition Examination Survey 2009-2018.

Peng X, Li Y, Wang X, Ruan Y, Liu N Front Cardiovasc Med. 2022; 9:739113.

PMID: 35498047 PMC: 9039360. DOI: 10.3389/fcvm.2022.739113.

References

Alexander V, Xia S, Hurh E, Hughes S, ODea L, Geary R . N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 2019; 40(33):2785-2796. PMC: 6736334. DOI: 10.1093/eurheartj/ehz209. View

Seuring T, Archangelidi O, Suhrcke M . The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015; 33(8):811-31. PMC: 4519633. DOI: 10.1007/s40273-015-0268-9. View

Onat A, Hergenc G, Ayhan E, Ugur M, Kaya H, Tuncer M . Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks. Diabet Med. 2009; 26(10):981-8. DOI: 10.1111/j.1464-5491.2009.02814.x. View

Aroner S, Yang M, Li J, Furtado J, Sacks F, Tjonneland A . Apolipoprotein C-III and High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III in Relation to Diabetes Risk. Am J Epidemiol. 2017; 186(6):736-744. DOI: 10.1093/aje/kwx143. View

Preacher K, Hayes A . SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput. 2005; 36(4):717-31. DOI: 10.3758/bf03206553. View

Russo G, Meigs J, Cupples L, Demissie S, Otvos J, Wilson P . Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis. 2001; 158(1):173-81. DOI: 10.1016/s0021-9150(01)00409-9. View

Gao S, Zhao D, Qi Y, Wang M, Zhao F, Sun J . The association between serum ferritin levels and the risk of new-onset type 2 diabetes mellitus: A 10-year follow-up of the Chinese Multi-Provincial Cohort Study. Diabetes Res Clin Pract. 2017; 130:154-162. DOI: 10.1016/j.diabres.2017.05.013. View

Crosby J, Peloso G, Auer P, Crosslin D, Stitziel N, Lange L . Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014; 371(1):22-31. PMC: 4180269. DOI: 10.1056/NEJMoa1307095. View

Jong M, Hofker M, Havekes L . Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999; 19(3):472-84. DOI: 10.1161/01.atv.19.3.472. View

10.

Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412-9. DOI: 10.1007/BF00280883. View

11.

Qi Y, Fan J, Liu J, Wang W, Wang M, Sun J . Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. J Am Coll Cardiol. 2015; 65(4):355-363. DOI: 10.1016/j.jacc.2014.11.019. View

12.

Korsiak J, Tranmer J, Day A, Aronson K . Sleep duration as a mediator between an alternating day and night shift work schedule and metabolic syndrome among female hospital employees. Occup Environ Med. 2017; 75(2):132-138. DOI: 10.1136/oemed-2017-104371. View

13.

Sundaram M, Zhong S, Bou Khalil M, Links P, Zhao Y, Iqbal J . Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res. 2009; 51(1):150-61. PMC: 2789775. DOI: 10.1194/M900346-JLR200. View

14.

. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403):157-63. DOI: 10.1016/S0140-6736(03)15268-3. View

15.

Zhang J, de Albuquerque Rocha N, McCullough P . Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen. Rev Cardiovasc Med. 2019; 19(1):13-19. DOI: 10.31083/j.rcm.2018.01.890. View

16.

Christopoulou E, Tsimihodimos V, Filippatos T, Elisaf M . Apolipoprotein CIII and diabetes. Is there a link?. Diabetes Metab Res Rev. 2018; 35(3):e3118. DOI: 10.1002/dmrr.3118. View

17.

Altman D, Bland J . Interaction revisited: the difference between two estimates. BMJ. 2003; 326(7382):219. PMC: 1125071. DOI: 10.1136/bmj.326.7382.219. View

18.

Aroner S, Furtado J, Sacks F, Tsai M, Mukamal K, McClelland R . Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis. Diabetologia. 2019; 62(6):981-992. DOI: 10.1007/s00125-019-4847-8. View

19.

Zewinger S, Reiser J, Jankowski V, Alansary D, Hahm E, Triem S . Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol. 2019; 21(1):30-41. DOI: 10.1038/s41590-019-0548-1. View

20.

Huth C, von Toerne C, Schederecker F, de Las Heras Gala T, Herder C, Kronenberg F . Protein markers and risk of type 2 diabetes and prediabetes: a targeted proteomics approach in the KORA F4/FF4 study. Eur J Epidemiol. 2019; 34(4):409-422. PMC: 6451724. DOI: 10.1007/s10654-018-0475-8. View